Syncor to distribute diagnostic radiopharmaceutical:
This article was originally published in Clinica
Syncor International will exclusively distribute Massachusetts General Hospital's F-18 Fluorodeoxyglucose (FDG), a diagnostic pharmaceutical for use in Positron Emission Tomography (PET). The Woodland Hill, California-based company will be responsible for actively marketing the product to increase usage of FDG, which is used in oncology, cardiology and neurology. The hospital has its own commercial nuclear pharmacy dedicated to FDG and a research budget of more than $200 million a year.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.